Literature DB >> 32399057

Correction to: The International/Canadian Hereditary Angioedema Guideline.

Stephen Betschel1, Jacquie Badiou2, Karen Binkley1, Rozita Borici-Mazi3, Jacques Hébert4, Amin Kanani5, Paul Keith6, Gina Lacuesta7, Susan Waserman6, Bill Yang8, Emel Aygören-Pürsün9, Jonathan Bernstein10, Konrad Bork11, Teresa Caballero12, Marco Cicardi13, Timothy Craig14, Henriette Farkas15, Anete Grumach16, Connie Katelaris17, Hilary Longhurst18, Marc Riedl19, Bruce Zuraw19, Magdelena Berger20, Jean-Nicolas Boursiquot21, Henrik Boysen22, Anthony Castaldo23, Hugo Chapdelaine24, Lori Connors7, Lisa Fu25, Dawn Goodyear26, Alison Haynes27, Palinder Kamra28, Harold Kim29,30, Kelly Lang-Robertson1, Eric Leith31, Christine McCusker32, Bill Moote33, Andrew O'Keefe27, Ibraheem Othman34, Man-Chiu Poon35, Bruce Ritchie36, Charles St-Pierre37, Donald Stark38, Ellie Tsai39.   

Abstract

[This corrects the article DOI: 10.1186/s13223-019-0376-8.].
© The Author(s) 2020.

Entities:  

Year:  2020        PMID: 32399057      PMCID: PMC7204235          DOI: 10.1186/s13223-020-00430-4

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


Correction to: Allergy Asthma Clin Immunol (2019) 15:72 10.1186/s13223-019-0376-8

Following the publication of this article [1], the authors requested to amend the characterisation of ‘lanadelumab’ from ‘humanised’ to the correct ‘fully human’. Therefore, the fourth paragraph under Recommendation #24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP…” Similarly, the first paragraph under Recommendation #27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/κ-light chain)…”
  1 in total

Review 1.  The International/Canadian Hereditary Angioedema Guideline.

Authors:  Stephen Betschel; Jacquie Badiou; Karen Binkley; Rozita Borici-Mazi; Jacques Hébert; Amin Kanani; Paul Keith; Gina Lacuesta; Susan Waserman; Bill Yang; Emel Aygören-Pürsün; Jonathan Bernstein; Konrad Bork; Teresa Caballero; Marco Cicardi; Timothy Craig; Henriette Farkas; Anete Grumach; Connie Katelaris; Hilary Longhurst; Marc Riedl; Bruce Zuraw; Magdelena Berger; Jean-Nicolas Boursiquot; Henrik Boysen; Anthony Castaldo; Hugo Chapdelaine; Lori Connors; Lisa Fu; Dawn Goodyear; Alison Haynes; Palinder Kamra; Harold Kim; Kelly Lang-Robertson; Eric Leith; Christine McCusker; Bill Moote; Andrew O'Keefe; Ibraheem Othman; Man-Chiu Poon; Bruce Ritchie; Charles St-Pierre; Donald Stark; Ellie Tsai
Journal:  Allergy Asthma Clin Immunol       Date:  2019-11-25       Impact factor: 3.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.